Homocystinuria
Homocystinuria is an autosomal recessive inborn error of methionine/homocysteine metabolism. Classical homocystinuria is cystathionine β-synthase (CBS) deficiency; non-classical forms include MTHFR (methylenetetrahydrofolate reductase) deficiency and cobalamin metabolism defects (CblC, CblD, CblE, CblF, CblG, CblJ). CBS deficiency phenotype spans (a) vascular/thrombotic disease — DVT, pulmonary embolism, stroke, often in children and young adults, with aortic disease; (b) ocular — ECTOPIA LENTIS (lens dislocation, pathognomonic) plus myopia, glaucoma, and retinal detachment; (c) skeletal — marfanoid habitus (tall, thin, arachnodactyly), pectus deformity, genu valgum, overlapping Marfan syndrome body morphology but with OSTEOPOROSIS instead of aortic root dilation; (d) CNS — intellectual disability, psychiatric disease, seizures; (e) hair/skin — fair complexion, fine hair. Hyperhomocysteinemia is the load-bearing biomarker and the proximate mechanism for vascular events. Newborn screening for elevated methionine is on the US RUSP; Ireland has the highest known prevalence (~1/65,000) and mandatory NBS; Qatari, Saudi, UAE, and Irish founder populations are well-characterized. Standard of care: PYRIDOXINE (Vitamin B6) RESPONSIVENESS in ~50% of CBS cases — high-dose pyridoxine 200–500 mg/day lowers homocysteine dramatically; B6-non-responsive cases require METHIONINE-RESTRICTED DIET + CYSTEINE SUPPLEMENTATION lifelong (Nutricia HCU Anamix, Mead Johnson Phenex-2 and similar medical foods); BETAINE (Cystadane, Recordati / Orphan Europe) FDA-approved 1996 — methyl donor for remethylation; FOLATE + B12 adjunct; aspirin or anticoagulation for thrombotic prophylaxis in select cases. PEGTIBATINASE (Travere Therapeutics) — recombinant CBS enzyme replacement in Phase 3 HARMONY trial — is the disease-modifying frontier. HCU Network America (hcunetworkamerica.org), European HCU Network, and SSIEM are the patient and professional organization anchors. Marfanoid habitus + ectopia lentis can drive misdiagnosis as Marfan syndrome — the differential is editorially load-bearing. Ninety-sixth deliberate non-elevation.
What changes during this transition
Homocystinuria arrives in the peptide-companion library along four predictable community-curiosity vectors, each of which fails on the same load-bearing reality: this is a Mendelian methionine/homocysteine metabolism disorder with multiple disease-modifying interventions already in place, and peptides do not address the upstream enzymatic defect. The first vector is the 'circulation' / 'vascular health' register — BPC-157 in particular. The community-peptide reflex for any patient who has had a DVT, PE, or stroke is to nominate BPC-157 because of its pro-angiogenic + nitric-oxide-releasing community framing. Homocystinuria patients carry exactly this thrombotic history — often presenting with cerebrovascular or venous thromboembolic events in childhood or young adulthood — and they are over-represented in the population probing /ask about 'vascular healing peptides.' The mechanism-vs-disease contradiction is sharper here than in almost any other axis in the library: homocysteine itself is an endothelial-dysfunction driver — it impairs nitric oxide bioavailability, promotes oxidative stress on the endothelium, and is mechanistically central to the thrombotic phenotype. A peptide marketed as 'pro-angiogenic / NO-releasing / vascular healing' in a homocysteine-driven vascular disease population is a register collision. Many homocystinuria patients are on aspirin or anticoagulation for thrombotic prophylaxis, which turns the subcutaneous-injection practical question into a bleeding-risk conversation. The second vector is the 'general-aging / longevity' register — NMN. As the aging cohort of homocystinuria patients grows, general-aging peptide curiosity arrives. NMN's NAD+ precursor framing has no homocystinuria-specific evidence. The standard-of-care load-bearing interventions are pyridoxine (if responsive), methionine-restricted diet, cysteine supplementation, betaine, folate, B12, and thrombotic prophylaxis. The third vector is the 'growth-hormone-axis / body composition' register — CJC-1295, ipamorelin, and tesamorelin. This is the editorially sharpest substrate in the batch and carries the cross-link to the Marfan substrate. In homocystinuria, the marfanoid habitus is real, and patients are often misdiagnosed as having Marfan syndrome before the homocysteine workup completes. But the skeletal pathology axis is different: Marfan is fibrillin-1 microfibril failure with aortic-root dilation; homocystinuria is homocysteine-driven collagen cross-linking failure with OSTEOPOROSIS as the dominant skeletal complication. GH-axis stimulation in a population with skeletal fragility + vascular thrombotic risk is a direction-of-effect concern that runs across all three GH-axis peptides — and tesamorelin's HIV-associated lipodystrophy FDA approval does NOT propagate (Rule 6). The fourth vector is the 'GLP-1 / weight management' register — semaglutide. The complication specific to homocystinuria is the interaction between GLP-1-mediated appetite suppression and the methionine-restricted diet + medical food + cysteine supplementation regimen. Reduced caloric intake can drive non-adherence to the medical-food protein source. What anchors homocystinuria management is well-defined. Newborn screening for elevated methionine is on the US RUSP and mandatory in Ireland (which has the highest known prevalence, ~1/65,000, driven by founder genetics; Qatari, Saudi, and UAE populations also carry well-characterized founder mutations). Pyridoxine (vitamin B6) responsiveness defines the treatment fork: ~50% of CBS-deficiency patients respond to high-dose pyridoxine 200–500 mg/day with dramatic homocysteine reduction; B6-non-responsive patients require lifelong methionine-restricted diet + cysteine supplementation, anchored on medical food (Nutricia HCU Anamix, Mead Johnson Phenex-2). Betaine (Cystadane, Recordati / Orphan Europe) — FDA-approved 1996 — provides a methyl donor for the alternative remethylation pathway. Folate and B12 supplementation support the remethylation cycle. Aspirin or anticoagulation is added for thrombotic prophylaxis. Pegtibatinase (Travere Therapeutics) — recombinant CBS enzyme replacement — is in the Phase 3 HARMONY trial and represents the genuinely active disease-modifying frontier. HCU Network America, the European HCU Network, and SSIEM are legitimate patient- and professional-organization first stops. The editorial posture across all five substrate entries is the same: peptides are not the conversation in homocystinuria, the metabolic team is the anchor, pyridoxine challenge defines the treatment fork, diet + cysteine + betaine + folate + B12 is the load-bearing intervention stack, thrombotic prophylaxis is the vascular-event-prevention axis, and the pegtibatinase HARMONY Phase 3 trial is the actionable disease-modifying frontier.
Important caveat
Homocystinuria is metabolic-team-anchored — your inherited metabolic disorders specialist (and, where relevant, your metabolic dietitian, hematology for thrombotic-event management, ophthalmology for ectopia lentis and lens-related complications, orthopedics for marfanoid-skeletal management, cardiology if aortic involvement, and maternal-fetal medicine during pregnancy) leads diagnosis, treatment-fork determination (B6-responsive vs B6-non-responsive), and surveillance. **PYRIDOXINE RESPONSIVENESS DEFINES THE TREATMENT FORK**: ~50% of CBS-deficiency patients respond to high-dose pyridoxine (vitamin B6) at 200–500 mg/day with substantial homocysteine reduction; B6-non-responsive patients require lifelong METHIONINE-RESTRICTED DIET + CYSTEINE SUPPLEMENTATION (Nutricia HCU Anamix, Mead Johnson Phenex-2 and equivalent medical foods) — the metabolic dietitian is non-negotiable. **BETAINE (Cystadane, Recordati / Orphan Europe) is FDA-approved (1996)** — methyl donor that lowers homocysteine via remethylation; standard across CBS deficiency and remethylation-defect forms. **FOLATE + B12** supplementation supports the remethylation cycle. **MTHFR deficiency + cobalamin-metabolism defects** (CblC, CblD, CblE, CblF, CblG, CblJ): betaine + folate + B12 + diet. **THROMBOTIC PROPHYLAXIS** is real — aspirin or anticoagulation for selected patients with prior thromboembolic events. **Newborn screening** (elevated methionine) is on the US RUSP and mandatory in Ireland (~1/65,000 prevalence — founder genetics; Qatari, Saudi, and UAE populations carry additional well-characterized founder mutations). **DIFFERENTIAL DIAGNOSIS WITH MARFAN SYNDROME IS LOAD-BEARING** — marfanoid habitus + ectopia lentis appear in both, but homocystinuria's skeletal pathology is OSTEOPOROSIS (not aortic-root dilation), the ectopia lentis displacement direction differs (typically DOWNWARD in homocystinuria vs UPWARD in Marfan), and the management is fundamentally different — total plasma homocysteine + plasma amino acids on every clinically suspected Marfan patient with ectopia lentis is the missed-diagnosis pattern that haunts these families. **PREGNANCY**: homocystinuria pregnancies are HIGH-RISK — thrombotic-event risk concentrates in pregnancy and postpartum; continue diet + betaine + B6 + folate + B12 unchanged or intensified; LMWH thromboprophylaxis is standard in many programs. **ECTOPIA LENTIS** lens dislocation can be the presenting feature and carries glaucoma, retinal detachment, and vision-loss risk — annual ophthalmology surveillance is the standard. **PEGTIBATINASE (Travere Therapeutics)** recombinant CBS enzyme replacement is in the Phase 3 HARMONY trial — this is the active disease-modifying frontier. **HCU Network America (hcunetworkamerica.org)**, European HCU Network, and SSIEM are legitimate patient and professional organization first stops. None of the peptides discussed in this substrate (BPC-157, NMN, CJC-1295, ipamorelin, tesamorelin, semaglutide) have controlled trial evidence in homocystinuria in any jurisdiction; the homocysteine-driven endothelial-dysfunction background makes the BPC-157 pro-angiogenic / NO-releasing framing a register collision specific to this disorder. Subcutaneous-injection peptides in patients on aspirin or anticoagulation for thrombotic prophylaxis raise a bleeding-risk question that has to be answered by the hematology and metabolic teams, not a peptide forum. WADA athletes: BPC-157 (S0), CJC-1295 / tesamorelin / ipamorelin (S2 growth-axis prohibited at all times), and semaglutide (not prohibited but disclose). This substrate is editorial honesty for /ask probing; it is not a recommendation to use any of these peptides in homocystinuria. **NO Juno library peptide is surfaced as a homocystinuria discovery card — 96th deliberate non-elevation**.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.